From: Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma
Baseline
PValue
Day 28
Day 56
Day 150
MEDI-528 (n = 7)*
-22.20 (4.38)
0.62
-6.49 (11.73)
0.22
-1.40 (2.27)
0.17
-5.04 (3.91)
0.52
Placebo (n = 2)
-20.20 (4.16)
-12.60 (1.53)
-20.10 (7.41)
-15.20 (15.48)